Most frequently used treatment modalities for pcALCL
| . | Skin directed . | Systemic . |
|---|---|---|
| Localized (T1, T2) | Radiotherapy,56-58 surgical excision3 | Low-dose methotrexate59 |
| Widespread localized (T2) or generalized (T3) with no regional node involvement | BV (preferred),23,73 low-dose methotrexate,59 retinoids,61,62 pralatrexate70 | |
| pcALCL with regional node involvement | BV (preferred),23,73 low-dose methotrexate,55,59 retinoids,61,62 pralatrexate,70 CHOP,8,53 RT55 |
| . | Skin directed . | Systemic . |
|---|---|---|
| Localized (T1, T2) | Radiotherapy,56-58 surgical excision3 | Low-dose methotrexate59 |
| Widespread localized (T2) or generalized (T3) with no regional node involvement | BV (preferred),23,73 low-dose methotrexate,59 retinoids,61,62 pralatrexate70 | |
| pcALCL with regional node involvement | BV (preferred),23,73 low-dose methotrexate,55,59 retinoids,61,62 pralatrexate,70 CHOP,8,53 RT55 |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone.